Skip to main content
Top
Published in: American Journal of Clinical Dermatology 3/2001

01-06-2001 | Therapy in Practice

Optimal Management of Acne to Prevent Scarring and Psychological Sequelae

Author: Dr Alison M. Layton

Published in: American Journal of Clinical Dermatology | Issue 3/2001

Login to get access

Abstract

Acne vulgaris is one of the most common inflammatory dermatoses and is seen in both the hospital setting and in general practice. Multiple factors are involved in the pathophysiology of acne, including: an alteration in the pattern of keratinization within the pilosebaceous follicles resulting in comedone formation; an increase in sebum production which is influenced by androgens; the proliferation of Propionibacterium acnes; and the production of perifollicular inflammation. Genetic and hormonal factors may also contribute to acne. Better understanding of the pathophysiology of the disease has led to the development of novel therapies which are directed at one or more of the implicated etiologic factors.
Systemic antibiotics for acne have been the mainstay of treatment for many years. The main cause for concern following the use of systemic antibiotics is the emergence of antibiotic-resistant strains of P. acnes. Concomitant use of non-antibiotic therapies such as benzoyl peroxide helps to decrease the occurrence of resistance and can be effective in the treatment of resistant and nonresistant propionibacterial strains. However, no one agent is able to eradicate resistant strains completely and as resistant strains correlate to poor clinical response to therapy, prescribing strategies are required to minimize the occurrence of resistance to P. acnes.
When assessing acne it is important to take an all embracing approach and to examine carefully for both the clinical and psychologic effects of the disease process. There are numerous forms of acne scarring and it is important to be aware of these as patients who are developing scarring merit early effective therapy. Some patients with acne will develop psychologic problems as a consequence of their condition. Even mild to moderate disease can be associated with significant depression and suicidal ideation and psychologic change does not necessarily correlate with disease severity. Acne scars themselves have been shown to produce significant psychopathology.
When initiating treatment it is important to consider the aims of therapy. Treatment should be aimed at achieving clearance of acne, prevention of scarring and, where necessary, relief from any psychologic stress resulting from the acne. Therapy should be commenced early in the disease process in order to prevent scarring and it is important to select appropriate therapies according to the clinical signs and psychologic disability. It is also important to ensure that the patient is able to comply with therapy and clear guidelines regarding treatment, possible adverse effects and realistic expectations should be provided.
Literature
1.
go back to reference Eady E.A., Cove J.H., Cunliffe W.J. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–57PubMedCrossRef Eady E.A., Cove J.H., Cunliffe W.J. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–57PubMedCrossRef
2.
go back to reference Lleyden J.J. Therapy for acne vulgaris — review article. N Engl J Med 1997; 336: 1156–1162CrossRef Lleyden J.J. Therapy for acne vulgaris — review article. N Engl J Med 1997; 336: 1156–1162CrossRef
3.
go back to reference Leyden J.J., McGinley K.H., Cavalierie S., et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–45PubMedCrossRef Leyden J.J., McGinley K.H., Cavalierie S., et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–45PubMedCrossRef
4.
go back to reference Farmery M.R., Jones C.E., Eady E.A., et al. In vitro activity of azeleic acid, benzoyl peroxide and zinc acetate against anti biotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994; 5: 63–65CrossRef Farmery M.R., Jones C.E., Eady E.A., et al. In vitro activity of azeleic acid, benzoyl peroxide and zinc acetate against anti biotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994; 5: 63–65CrossRef
5.
go back to reference Bojar R.A., Eady E.A., Jones C.E., et al. Inhibition of erythromycin resistant propionibacteria on the skin of acne patients by combining topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329–336PubMedCrossRef Bojar R.A., Eady E.A., Jones C.E., et al. Inhibition of erythromycin resistant propionibacteria on the skin of acne patients by combining topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329–336PubMedCrossRef
6.
go back to reference Eady E.A., Bojar R.A., Jones C.E., et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996; 134: 107–113PubMedCrossRef Eady E.A., Bojar R.A., Jones C.E., et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996; 134: 107–113PubMedCrossRef
7.
go back to reference Coates P., Adams C.A., Cunliffe W. Does oral isotretinoin prevent propionibacterium acnes resistance? Dermatology 1997; 195 Suppl. 4–9PubMedCrossRef Coates P., Adams C.A., Cunliffe W. Does oral isotretinoin prevent propionibacterium acnes resistance? Dermatology 1997; 195 Suppl. 4–9PubMedCrossRef
8.
go back to reference Eady E.A., Jones C.E., Tipper, LE, et al. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1997; 306 (6877): 555–556CrossRef Eady E.A., Jones C.E., Tipper, LE, et al. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1997; 306 (6877): 555–556CrossRef
9.
go back to reference Kirkup M.E., Dunill M.C.S. Management of acne prior to referral for isotretinoin therapy. Br J Dermatol 1999; 141 Suppl. 55: 53 Kirkup M.E., Dunill M.C.S. Management of acne prior to referral for isotretinoin therapy. Br J Dermatol 1999; 141 Suppl. 55: 53
10.
11.
go back to reference Sulzberger M.B., Zaidens S.H. Psychogenic factors in dermatologic disorders. Med Clin North Am 1948; 32: 669PubMed Sulzberger M.B., Zaidens S.H. Psychogenic factors in dermatologic disorders. Med Clin North Am 1948; 32: 669PubMed
12.
go back to reference Kenyon F.E. Psychosomatic aspects of acne. Br J Dermatol 1966; 78: 344–351CrossRef Kenyon F.E. Psychosomatic aspects of acne. Br J Dermatol 1966; 78: 344–351CrossRef
13.
go back to reference Rubinov D.R. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987; 17 (1): 25–32CrossRef Rubinov D.R. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987; 17 (1): 25–32CrossRef
14.
go back to reference Shuster S., Fisher G.H., Harris E., et al. The effect of skin disease on self image. Br J Dermatol 1978; 99 Suppl. 16: 18–19PubMedCrossRef Shuster S., Fisher G.H., Harris E., et al. The effect of skin disease on self image. Br J Dermatol 1978; 99 Suppl. 16: 18–19PubMedCrossRef
15.
go back to reference van der Meeram H.L., van der Schoor W.W., van der Hib C.M. The psychological impact of severe acne. Cutis 1985; 36: 84–86 van der Meeram H.L., van der Schoor W.W., van der Hib C.M. The psychological impact of severe acne. Cutis 1985; 36: 84–86
16.
go back to reference Gupta M.A., Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia, areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846–850PubMedCrossRef Gupta M.A., Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia, areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846–850PubMedCrossRef
17.
go back to reference Seukeran D.C., Cunliffe W.J., Islam J., et al. The psychological impact of acne scarring. Br J Dermatol 1999; 144 Suppl. 55: 54 Seukeran D.C., Cunliffe W.J., Islam J., et al. The psychological impact of acne scarring. Br J Dermatol 1999; 144 Suppl. 55: 54
18.
go back to reference Brosden R.N., Goa R.L. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997; 53 (5): 511–519CrossRef Brosden R.N., Goa R.L. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997; 53 (5): 511–519CrossRef
19.
go back to reference Cunliffe W.J., Holland K.T. The effect of benzoyl peroxide on acne. Acta Dermatol Venereol 1981; 61: 267–269 Cunliffe W.J., Holland K.T. The effect of benzoyl peroxide on acne. Acta Dermatol Venereol 1981; 61: 267–269
20.
go back to reference Eady E.A., Cove J.H., Jones D.N., et al. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat 1990; 1: 215–218CrossRef Eady E.A., Cove J.H., Jones D.N., et al. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat 1990; 1: 215–218CrossRef
21.
go back to reference Chu T. The role of topical retinoids in the treatment of acne. CME Dermatol Bull 2000; 2: 53–55 Chu T. The role of topical retinoids in the treatment of acne. CME Dermatol Bull 2000; 2: 53–55
22.
go back to reference Eady E.A., Jones C.E., Tipper C.L. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993; 306: 555–556PubMedCrossRef Eady E.A., Jones C.E., Tipper C.L. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993; 306: 555–556PubMedCrossRef
23.
go back to reference Cunliffe W.J.. Propionibacteria acnes resistance and its clinical relevance. J Dermatol Treat 1995; 6 (Suppl. 1): 53–54 Cunliffe W.J.. Propionibacteria acnes resistance and its clinical relevance. J Dermatol Treat 1995; 6 (Suppl. 1): 53–54
24.
go back to reference Greenwood K., Brommitt I.L., Burke B. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen cyproterone acetate and combined treatment. BMJ 1985; 291: 1231–1235PubMedCrossRef Greenwood K., Brommitt I.L., Burke B. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen cyproterone acetate and combined treatment. BMJ 1985; 291: 1231–1235PubMedCrossRef
25.
go back to reference Hammerstein J., Meckier J., Leo-Rossburg I., et al. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975; 6: 827–836PubMedCrossRef Hammerstein J., Meckier J., Leo-Rossburg I., et al. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975; 6: 827–836PubMedCrossRef
27.
go back to reference Layton A.M., Hughes B.R., MacDonald-Hull S., et al. Seborrhoea — an indicator for clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992; 17: 173–175PubMedCrossRef Layton A.M., Hughes B.R., MacDonald-Hull S., et al. Seborrhoea — an indicator for clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992; 17: 173–175PubMedCrossRef
28.
go back to reference Layton A.M., Knaggs H., Taylor J., et al. Isotretinoin for acne vulgaris — 10 years later: a safe and successful treatment. Br J Dermatol 1993; 129: 292–296PubMedCrossRef Layton A.M., Knaggs H., Taylor J., et al. Isotretinoin for acne vulgaris — 10 years later: a safe and successful treatment. Br J Dermatol 1993; 129: 292–296PubMedCrossRef
29.
go back to reference Millard L. Adverse mood and behaviour change in young patients on systemic isotretinoin. Br J Dermatol 1999; 141 Suppl. 55: 16 Millard L. Adverse mood and behaviour change in young patients on systemic isotretinoin. Br J Dermatol 1999; 141 Suppl. 55: 16
30.
go back to reference Lee M.L., Cooper A. Isotretinoin: cost benefit study. Aust J Dermatol 1991; 32: 17–20CrossRef Lee M.L., Cooper A. Isotretinoin: cost benefit study. Aust J Dermatol 1991; 32: 17–20CrossRef
31.
go back to reference Cunliffe W.J., van der Kerkhof P.C.M., Capcto R., et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351–357PubMedCrossRef Cunliffe W.J., van der Kerkhof P.C.M., Capcto R., et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351–357PubMedCrossRef
32.
go back to reference Newton J.N., Mullan E., Klassen A., et al. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137 (4): 563–567PubMedCrossRef Newton J.N., Mullan E., Klassen A., et al. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137 (4): 563–567PubMedCrossRef
33.
go back to reference Kellet S., Gawkrodger D.J.. The psychological and emotional impact of chronic acne and the effect of treatment with isotretinoin. Br J Dermatol 1998; 139 Suppl. 51: 56 Kellet S., Gawkrodger D.J.. The psychological and emotional impact of chronic acne and the effect of treatment with isotretinoin. Br J Dermatol 1998; 139 Suppl. 51: 56
Metadata
Title
Optimal Management of Acne to Prevent Scarring and Psychological Sequelae
Author
Dr Alison M. Layton
Publication date
01-06-2001
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 3/2001
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200102030-00002

Other articles of this Issue 3/2001

American Journal of Clinical Dermatology 3/2001 Go to the issue

Adis New Drug Profile

Topical Eflornithine

Review Article

Vitiligo

Adis New Drug Profile

Topical Eflornithine